SUNDAY, JANUARY 29
Arrival and Registration

MONDAY, JANUARY 30
Welcome and Keynote Address
Crystal L. Mackall, Stanford University, USA
CAR T Cells for Solid Tumors

Successes and Challenges of Cancer Immunotherapies in the Clinic
Nirali N. Shah, NCI, National Institutes of Health, USA
CAR T Cells
Rayne H. Rouce, Baylor College of Medicine, USA
Native T Cells for ACT
Marcela V. Maus, Harvard Medical School, USA
Novel CAR T Targets
Tanja D. de Gruijl, Vrije Universiteit Amsterdam, Netherlands
Cancer Vaccines

Workshop 1: Manufacturing Cell Therapies
Short Talks Chosen from Abstracts
T-Cell Factors Affecting the Potency of Cancer Immunotherapies
Carl H. June, University of Pennsylvania, USA
Persistence of Engineered T-Cells, Site of CAR Vector Insertion
Nicholas P. Restifo, Lyell, USA
T Memory Stem Cells Trigger Curative Immunotherapy
Marco Davila, Moffitt Cancer Center, USA
Mechanisms of Resistance to CAR T Cells in Hematologic Malignancies

Short Talks Chosen from Abstracts
Poster Session 1

TUESDAY, JANUARY 31
Conditional Reprogramming of CAR T-Cells
Francesco M. Marincola, Kite Pharma, USA
Synthetic Biology Approaches to Increase Specificity and Versatility
Daniel J. Powell, University of Pennsylvania, USA
Inducible Programming of CAR T cell Function and Intrinsic Properties for Cancer Immunotherapy
Robbie G. Majzner, Stanford University School of Medicine, USA
Coopting T Cell Signaling Networks for Enhanced CAR T Cell Specificity and Efficacy

Short Talks Chosen from Abstracts
Workshop 2: Equipment and Regents for Cell Therapy Problem Solving
Short Talks Chosen from Abstracts

Improving Expansion and Persistence Adoptive T-Cell Therapies
Justin Eyquem, University of California, San Francisco, USA
Modification of CAR Signaling Domain
Sine Reker Hadrup, Technical University of Denmark, Denmark
Endogenous Retroviral Targets of T Cell Response in Multiple Types of Therapy
Yvonne Y. Chen, University of California, Los Angeles, USA
Advances in T-Cell Engineering

Short Talks Chosen from Abstracts
Poster Session 2

WEDNESDAY, FEBRUARY 1
Cell Trafficking and Modulating the Tumor Microenvironment
Caetano Reis e Sousa, Francis Crick Institute, UK
Dendritic Cell Biology
Andreas Lundqvist, Karolinska Institutet, Sweden
NK Cells
Stephen Gottschalk, St. Jude Children's Research Hospital, USA
ECM-Targeted T Cell Therapy for Solid Tumors
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, USA
Targeting Solid Malignancies With Patient-Derived ‘Public’ Neoantigen TCRs

Short Talks Chosen from Abstracts
Career Roundtable
Engineering Improved T-Cells
Kole T. Roybal, University of California, San Francisco, USA
Engineering T-Cells to Express Receptors Targeting Multiple Antigens
Wilson Wong, Boston University, USA
Engineering CAR Circuits
Lei (Stanley) Qi, Stanford University, USA
Epigenetic Regulation of CAR-T Cells using CRISPR

Short Talks Chosen from Abstracts
Poster Session 3

THURSDAY, FEBRUARY 2
Novel Targets and the Role of Endogenous Antigen Presentation
Catherine J. Wu, Dana-Farber Cancer Institute, USA
T-Cell Therapy using Neoantigen Reactive TCRs
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, USA
T-Cell Therapy using Engineered TCRs
Lisa H. Butterfield, Parker Institute for Cancer Immunotherapy, USA
Critical Aspects of DC Metabolism
Michael Klichinsky, Carisma Therapeutics, USA
CAR Macrophages for Solid Tumor Immunotherapy

Short Talks Chosen from Abstracts
Allogeneic Immunotherapies

* Session Chair † Invited but not yet accepted     Program current as of November 17, 2022. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
Barbra Sasu, Allogene Therapeutics, USA
Engineering T-Cell to Prevent Immune Rejection and GVHD

Speaker to be Announced

David F. Stroncek, National Institutes of Health, USA
Optimizing Engineered T Cell Manufacturing

Short Talks Chosen from Abstracts

Meeting Wrap-Up and Future Directions (Organizers)

FRIDAY, FEBRUARY 3

Departure